Premium
Interleukin‐15‐transferred cytokine‐induced killer cells elevated anti‐tumor activity in a gastric tumor‐bearing nude mice model
Author(s) -
Peng Zheng,
Liang Wentao,
Li Zexue,
Xu Yingxin,
Chen Lin
Publication year - 2016
Publication title -
cell biology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.932
H-Index - 77
eISSN - 1095-8355
pISSN - 1065-6995
DOI - 10.1002/cbin.10553
Subject(s) - cytokine , tumor cells , cancer research , immunology , medicine , biology
Gastric cancer is the second leading cause of cancer‐related mortality worldwide. Adoptive cell therapy (ACT) for gastric cancer is a novel therapy modality. However, the therapeutic effectiveness in vivo is still limited. The objective of this study was to assess the value of interleukin‐15 (IL‐15)‐transferred cytokine‐induced killer (CIK) cells in ACT for gastric cancer. IL‐15‐IRES‐TK retroviral vector was constructed and transferred into the CIK cells. A gastric tumor‐bearing nude mice model was constructed by subcutaneously injecting gastric cancer cells, BGC‐823. Gastric tumor‐bearing nude mice were randomly divided into three groups (five mice each group) and injected with physiological saline, CIK cells, and IL‐15‐IRES‐TK‐transfected CIK cells for 2 weeks, respectively. IL‐15‐IRES‐TK‐transferred CIK cells were prepared successfully and flow cytometry (FCM) analysis indicated that the transfection rate reached 85.7% after 5 days culture. In vivo experiment, we found that CIK cells retarded tumor growth by reducing tumor volume and tumor weight, as well as increasing tumor inhibition rate. Furthermore, IL‐15‐IRES‐TK‐transferred CIK cells showed a much stronger inhibition on tumor growth than CIK cells alone. Tumor morphology observation and growth indexes also showed that IL‐15‐transfected CIK cells had stronger cytotoxicity to tumor tissue than CIK cells. IL‐15‐IRES‐TK transfection could elevate the effects of CIK cells to gastric carcinoma. The engineered CIK cells carrying IL‐15‐IRES‐TK may be used in the ACT for gastric carcinoma, but prudent clinical trial is still indispensable.